Advertisement
Organisation › Details
Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending. Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over €70 million in funding since inception. *
Start | 1999-01-01 established | |
Street | 8 Rue de la Croix Jarry | |
City | 75013 Paris | |
Tel | +33-1-8169-1600 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2019-12-31) |
Currency | USD | |
Annual sales | 22,990,000 (income, total, consolidated (2019) 2019-12-31) | |
Profit | -115,212,000 (2019-12-31) | |
Cash | 340,522,000 (2019-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Cellectis (Group)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top